Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 3/20 | 0.35 |
| ▸ | TET3 | O43151 | 1/20 | 0.35 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30638082 | 0.86 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL29087904 | 0.86 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL1610399 | 0.79 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL9044977 | 0.77 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL6484046 | 0.77 | SELE (0.39) | MEN1KMT2A | |
| SCHEMBL14330745 | 0.76 | SLC6A3 (0.36) | MEN1KMT2A | |
| SCHEMBL4100097 | 0.74 | CA2 (0.38) | MEN1KMT2A | |
| SCHEMBL26187811 | 0.74 | MEN1 (0.44) | MEN1KMT2A | |
| SCHEMBL8637033 | 0.73 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL30989292 | 0.72 | MEN1 (0.38) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | PIRAMAL IMAGING SA (CH) | 2012-12-27 | — | — | US | disclosed |
| EP-2338892-A1 | Prostate specific membrane antigen inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, ACP3 | TET2 4860/4885TET3 4807/4885TET1 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.